Publicaciones en las que colabora con Antonio Rivero Román (36)

2023

  1. Response to glecaprevir/pibrentasvir in HIV/HCV-coinfected patients in clinical practice

    Journal of Antimicrobial Chemotherapy, Vol. 78, Núm. 10, pp. 2591-2596

2021

  1. Kinetics of emergence of liver complications in hepatitis C virus infected patients and advanced fibrosis, with and without HIV-coinfection, after sustained virological response

    AIDS (London, England), Vol. 35, Núm. 13, pp. 2119-2127

  2. Progression to hepatitis C virus micro-elimination in people living with HIV in Spain

    Clinical Microbiology and Infection

2020

  1. Executive summary: Consensus document of the diagnosis, management and prevention of infection with the hepatitis E virus: Study Group for Viral Hepatitis (GEHEP) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC)

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, Núm. 1, pp. 28-32

  2. Using machine learning methods to determine a typology of patients with HIVHCV infection to be treated with antivirals

    PLoS ONE, Vol. 15, Núm. 1

  3. What is needed to achieve HCV microelimination among HIV-infected populations in Andalusia, Spain: A modeling analysis

    BMC Infectious Diseases, Vol. 20, Núm. 1

2019

  1. Early emergence of opportunistic infections after starting direct-acting antiviral drugs in HIV/HCV-coinfected patients

    Journal of Viral Hepatitis, Vol. 26, Núm. 1, pp. 48-54

  2. Evaluation of hepatitis C viral RNA persistence in HIV-infected patients with long-term sustained virological response by droplet digital PCR

    Scientific Reports, Vol. 9, Núm. 1

  3. Parenteral drug use as the main barrier to hepatitis C treatment uptake in HIV-infected patients

    HIV Medicine, Vol. 20, Núm. 6, pp. 359-367

  4. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy

    Journal of Hepatology, Vol. 71, Núm. 1, pp. 45-51

  5. Similar recovery of liver function after response to all-oral HCV therapy in patients with cirrhosis with and without HIV coinfection

    Journal of Viral Hepatitis, Vol. 26, Núm. 1, pp. 16-24

2018

  1. Paritaprevir/ritonavir/ombitasvir plus dasabuvir in HIV/HCV-coinfected patients with genotype 1 in real-life practice

    HIV Clinical Trials, Vol. 19, Núm. 1, pp. 23-30

  2. Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis

    Journal of Antimicrobial Chemotherapy, Vol. 73, Núm. 9, pp. 2435-2443

2017

  1. Fat mass and obesity-associated gene variations are related to fatty liver disease in HIV-infected patients

    HIV Medicine, Vol. 18, Núm. 8, pp. 546-554

  2. Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 36, Núm. 3, pp. 487-494

  3. Liver stiffness predicts variceal bleeding in HIV/HCVcoinfected patients with compensated cirrhosis

    AIDS, Vol. 31, Núm. 4, pp. 493-500

  4. Spontaneous clearance of chronic hepatitis C is rare in HIV-infected patients after effective use of combination antiretroviral therapy

    PLoS ONE, Vol. 12, Núm. 5

  5. Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection

    Clinical Microbiology and Infection, Vol. 23, Núm. 6, pp. 409.e5-409.e8

2016

  1. Liver toxicity of current antiretroviral regimens in HIV-infected patients with chronic viral hepatitis in a real-life setting: The HEPAVIR SEG-HEP Cohort

    PLoS ONE, Vol. 11, Núm. 2

2015

  1. Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 34, Núm. 11, pp. 2247-2255